Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 14/305,402, filed Jun 16, 2014. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,028,156 | Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS In force · High confidence | Armagen, Inc. | In force | High confidence | ||
| US 8,834,874 | Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS In force · High confidence | JCR Pharmaceuticals Co., Ltd. | In force | High confidence | ||
| US 12,043,661 | Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS In force · High confidence | Armagen, Inc. | In force | High confidence | ||
| US 10,011,651 | Methods and Compositions for Increasing Iduronate 2-Sulfatase Activity in the CNS In force · High confidence | JCR Pharmaceuticals Co., Ltd. | In force | High confidence | ||
| Application 18/740,035 | Methods and Compositions for Increasing Iduronate 2-Sulfate Activity in the CNS Pending Not granted | ArmaGen, Inc. | Pending | Not granted | ||
| Application 19/401,802 | Pharmaceutical Agents for Increasing Iduronate 2-Sulfatase Activity in the CNS Pending Not granted | Armagen Technologies, Inc. | Pending | Not granted |
6 of 6 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Armagen, Inc..
Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.